Travere licenses BTK drug civorebrutinib from Everest

Travere Therapeutics entered a major license and collaboration agreement with Everest Medicines for civorebrutinib (EVER001), a covalent reversible Bruton’s tyrosine kinase inhibitor.

Rhea-AI Filing Summary

Travere Therapeutics entered a major license and collaboration agreement with Everest Medicines for civorebrutinib (EVER001), a covalent reversible Bruton’s tyrosine kinase inhibitor. Travere receives exclusive rights to develop and commercialize the drug for prophylactic, diagnostic and therapeutic uses in a broad field across territories outside China and certain East and Southeast Asian countries.

Travere will pay Everest an upfront $112.5 million, with Everest eligible for up to approximately $1.03 billion in additional clinical, regulatory and commercial milestone payments across up to five indications, plus tiered royalties from high single-digit to double-digit percentages on net sales. Travere leads development and commercialization in its territory, shares costs for global trials, and both parties agree to a 10‑year non-compete on competing BTK products. The agreement becomes effective after customary conditions, including expiration or termination of the Hart‑Scott‑Rodino waiting period.

Insights

Biopharma licensing analyst

Travere secures broad ex‑Asia rights to a BTK inhibitor with sizable upfront and milestone commitments.

Travere Therapeutics is expanding its pipeline by licensing civorebrutinib (EVER001) from Everest Medicines. Travere gains exclusive rights in most global markets outside China and parts of East and Southeast Asia for a wide prophylactic, diagnostic and therapeutic field, with Everest retaining its existing territories.

Financially, Travere commits to an upfront $112.5 million payment and up to about $1.03 billion in potential milestones across as many as five indications, plus tiered royalties from high single-digit to double-digit percentages on territorial net sales. The companies will share costs for global clinical trials, while Travere assumes primary development and commercialization responsibilities in its territory.

Risks highlighted include dependence on successful clinical development, regulatory approvals for both the transaction (including Hart‑Scott‑Rodino clearance) and eventual products, manufacturing scale‑up, market acceptance, and the company’s broader financing and competitive environment. Forward‑looking statements emphasize that outcomes for civorebrutinib and the collaboration remain uncertain and subject to these factors.

8-K Event Classification

2 items: 1.01, 9.01

2 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Upfront payment to Everest: $112.5 million Potential milestone payments: approximately $1.03 billion Royalty range: high single-digit to double-digit percentages +2 more

5 metrics

Upfront payment to Everest $112.5 million Cash payment due from Travere under license agreement

Potential milestone payments approximately $1.03 billion Clinical, regulatory and commercial milestones across up to five indications

Royalty range high single-digit to double-digit percentages Tiered royalties on annual net sales of products in the territory

Non-compete period 10 years Mutual restriction on competing BTK products in the field from effective date

Royalty term minimum 10 years from first commercial sale One of several triggers ending royalty obligations per country and product

Key Terms

covalent reversible Bruton’s tyrosine kinase inhibitor, Hart-Scott-Rodino Antitrust Improvements Act of 1976, regulatory exclusivity, commercially reasonable efforts, +1 more

5 terms

covalent reversible Bruton’s tyrosine kinase inhibitor medical

"civorebrutinib (also known as EVER001), a covalent reversible Bruton’s tyrosine kinase (“BTK”) inhibitor"

Hart-Scott-Rodino Antitrust Improvements Act of 1976 regulatory

"including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976"

regulatory exclusivity regulatory

"the expiration of the regulatory exclusivity of the Product in such country"

A period during which regulators prevent competitors from relying on a drug or device maker’s safety and effectiveness data to win approval for their own rival product, creating a temporary market shield beyond or instead of a patent. For investors, this delay in direct competition can extend a product’s revenue runway and improve predictable cash flow, like giving a seller exclusive access to a popular storefront for a set time before others can move in.

commercially reasonable efforts financial

"the Company is obligated to use commercially reasonable efforts to develop and, seek and obtain regulatory approval"

material definitive agreement regulatory

"Item 1.01 Entry into a Material Definitive Agreement"

A material definitive agreement is a legally binding contract that creates major, long‑term obligations or rights for a company, such as loans, asset sales, mergers, or supplier deals. Think of it like a mortgage or lease for a business: it can change future cash flow, risk and control, so investors watch these agreements closely because they can materially affect a company’s value, financial health and stock price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What agreement did Travere Therapeutics (TVTX) enter with Everest Medicines?

Travere signed a license and collaboration agreement with Everest Medicines for civorebrutinib. Travere gains exclusive rights to develop and commercialize the BTK inhibitor in a broad field across territories outside China and certain East and Southeast Asian countries, while collaborating on global clinical trials.

What are the key financial terms of Travere Therapeutics’ BTK license deal?

Travere will pay Everest an upfront $112.5 million and up to approximately $1.03 billion in additional clinical, regulatory and commercial milestone payments. Everest will also receive tiered royalties from high single-digit to double-digit percentages on Travere’s net sales of civorebrutinib-based products in the licensed territory.

Which territories and indications are covered in the Travere (TVTX) and Everest civorebrutinib deal?

Travere receives rights to civorebrutinib for prophylactic, diagnostic and therapeutic uses in all countries outside China and certain East and Southeast Asian countries. The agreement spans multiple potential immune-mediated kidney disease indications, with milestones tied to up to five specific indications over time.

How will Travere Therapeutics and Everest share development responsibilities for civorebrutinib?

Travere and Everest will collaborate and share costs on global clinical trials for civorebrutinib-based products. Aside from these global trials, Everest’s ongoing study and certain CMC activities, Travere is responsible for development and solely responsible for commercialization of products within its licensed territory under the agreement.

What non-compete and royalty terms apply in Travere’s BTK inhibitor agreement?

For ten years from the effective date, each party is restricted from developing, manufacturing or commercializing competing BTK products in the defined field, subject to limited exceptions. Travere will pay Everest tiered royalties, from high single-digit to double-digit percentages, on net sales of licensed products in its territory.

When does the Travere–Everest civorebrutinib agreement become effective?

The agreement becomes effective once customary conditions are satisfied, including expiration or termination of the applicable waiting period under the Hart‑Scott‑Rodino Antitrust Improvements Act of 1976. After effectiveness, the collaboration, payment obligations and development responsibilities outlined in the agreement will apply.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 07:05 AM Learn about SEC filing dates

false 0001438533 0001438533 2026-06-01 2026-06-01

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 1, 2026

TRAVERE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-36257		27-4842691
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

3611 Valley Centre Drive, Suite 300

San Diego, CA 92130

(Address of Principal Executive Offices, including Zip Code)

(888) 969-7879

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		TVTX		The Nasdaq Global Market

Item 1.01 Entry into a Material Definitive Agreement.

On June 1, 2026, Travere Therapeutics, Inc. (the “Company”) entered into a license and collaboration agreement (the “Agreement”) with Everest Medicines (Singapore) Pte. Ltd. (“Everest”), pursuant to which Everest grants an exclusive license to the Company for the development and commercialization of civorebrutinib (also known as EVER001), a covalent reversible Bruton’s tyrosine kinase (“BTK”) inhibitor, and products containing civorebrutinib (“Products”) for any and all prophylactic, diagnostic and therapeutic uses and treatment of diseases and disorders (the “Field”) in all countries outside of China and certain countries in East and Southeast Asia (the “Territory”).

Under the Agreement, the Company is granted (a) an exclusive, royalty-bearing license, with the right to grant sublicenses, under certain patents and know-how owned or controlled by Everest solely to make, have made, import, have imported, export, have exported, distribute, have distributed, use, have used, sell, have sold, offer for sale, or have offered for sale, including to develop, manufacture, and commercialize (“Exploit”), civorebrutinib and Products in the Field in the Territory; and (b) a non-exclusive license under certain patents and know-how owned or controlled by Everest to research, conduct non-clinical development for, or manufacture or have manufactured civorebrutinib and Products outside of the Territory solely for the purpose of Exploiting the Products in the Field in the Territory. The license granted to the Company by Everest includes a sublicense to certain patents and know-how owned by third parties, and the Company is required to comply with the terms and conditions of the relevant agreement between Everest and such third parties that are applicable to the Company as a sublicensee. In addition, until Everest has paid a fee to such third party licensors for uses of Products outside of the field of renal disease and conditions, the Company may not exercise its rights under the license with respect to any use outside of that field. Everest is obligated to make such payment following its receipt of the upfront payment from the Company described below. Under the terms of the Agreement, the Company grants to Everest a non-exclusive, fully paid, royalty-free license, with the right to grant sublicenses under intellectual property generated and owned by the Company under the Agreement to Exploit civorebrutinib and Products solely in the Field outside of the Territory.

The Company will collaborate and share development costs with Everest to conduct global clinical trials for Products. Except for such global trials, Everest’s ongoing clinical trial, and certain CMC development activities, the Company is responsible for development of Products in the Territory. The Company is solely responsible for commercialization of Products in the Territory. Under the terms of the Agreement, the Company is obligated to use commercially reasonable efforts to develop and, seek and obtain regulatory approval for at least one Product in the Field, and to commercialize Products, in the United States and additional major market countries. In addition, for a period of ten (10) years from the effective date of the Agreement, each party is prohibited from developing, manufacturing or commercializing any competing BTK product in the Field, subject to certain exceptions in the case of a change of control or acquisition.

Under the terms of the Agreement, the Company is obligated to pay Everest an upfront payment of $112.5 million. Everest is also eligible to receive up to approximately $1.03 billion in additional cash payments tied to specified clinical development, regulatory and commercial milestones across up to five indications. The Company is also obligated to pay Everest tiered royalties on net sales of Products in the Territory, ranging from high single-digit to double-digit percentages based on annual net sales thresholds. The royalties owed to Everest are subject to certain customary reductions. On a country-by-country and Product-by-Product basis, the Company’s obligation to pay royalties commences on the date of the first commercial sale of such Product in such country and continues until the latest of: (a) the expiration of the last-to-expire claim of a patent licensed to the Company by Everest that covers the composition of matter, formulations, or all approved methods of use set forth in the regulatory approval of such Product in such country; (b) the expiration of the regulatory exclusivity of the Product in such country; and (c) ten (10) years following the first commercial sale of such Product in such country.

The Agreement will become effective upon satisfaction of customary conditions, including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

The Agreement will remain in effect, unless terminated earlier, until the expiration of the royalty term for all Products in the Territory. Each party has the right to terminate the Agreement for the other party’s uncured material breach or insolvency. The Company has the right to terminate the Agreement in its entirety or on a region-by-region basis. The Company also has the right to terminate the Agreement, and be reimbursed for the upfront payment, if Everest does not timely complete its initial technology transfer obligations. Everest has the right to terminate the Agreement if the Company challenges any patent licensed to the Company by Everest, subject to certain customary exceptions. Everest also has the right to terminate the Agreement if the Company ceases all material development, manufacture and commercialization activities for Products for a continuous period of twelve (12) months or longer, subject to certain exceptions. Following early termination of the Agreement, the Company is required to grant a worldwide, exclusive license to Everest under the intellectual property generated by the Company under the Agreement to Exploit civorebrutinib and Products in the Field worldwide and to transfer or grant a right of reference to Everest for all regulatory filings and approvals for Products held by the Company.

The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2026.

Forward-Looking Statements

This Current Report on Form 8-K contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, these statements are often identified by the words “on-track,” “positioned,” “look forward to,” “will,” “would,” “may,” “might,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “potential,” or similar expressions. In addition, expressions of strategies, intentions or plans are also forward-looking statements. Such forward-looking statements include, but are not limited to, references to: statements and expectations regarding the potential of civorebrutinib to serve as a pipeline-in-a-product and to potentially become a best-in-class therapy across multiple immune-mediated kidney diseases, and its potential to provide differentiated efficacy, safety and convenience for the indications described herein; statements and expectations regarding the expected broad mechanistic applicability across diseases; statements and expectations regarding future treatment approaches and paradigms; statements and expectations regarding the clinical studies and data described herein; statements and expectations regarding potential future payments (including upfront, milestone and royalty payments) and potential development cost-sharing obligations and, as applicable, the potential achievement and timing thereof; statements and expectations regarding the activities of the Company’s partners and collaborators; and statements related to the estimated sizes of patient populations. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties related to the license agreement with Everest, including the ability of the parties to obtain required regulatory approvals and satisfy other applicable conditions, and the ability of the Company to successfully advance the product through clinical trials toward potential future regulatory approval. The Company also faces risks and uncertainties related to its business and finances in general, the success of its commercial products, risks and uncertainties associated with its preclinical and clinical stage pipeline, risks and uncertainties associated with the regulatory review and approval process, risks and uncertainties associated with enrollment of clinical trials for rare diseases, and risks that ongoing or planned clinical trials may not succeed or may be delayed for safety, regulatory or other reasons. Specifically, the Company faces risks associated with the commercial launch of FILSPARI in FSGS and commercial investments in IgAN, the timing and potential outcome of its and its partners’ clinical studies, market acceptance of its commercial products including efficacy, safety, price, reimbursement, and benefit over competing therapies, risks related to the challenges of manufacturing scale-up, risks associated with the successful development and execution of commercial strategies for such products, including FILSPARI, and risks and uncertainties related to the current administration, including but not limited to risks and uncertainties related to tariffs and the funding, staffing and prioritization of resources at government agencies including the FDA. The Company also faces the risk that it will be unable to raise additional funding that may be required to complete development of any or all of its product candidates, including as a result of macroeconomic conditions; risks relating to the Company’s dependence on contractors for clinical drug supply and commercial manufacturing; uncertainties relating to patent protection and exclusivity periods and intellectual property rights of third parties; risks associated with regulatory interactions; and risks and uncertainties relating to competitive products, including current and potential future generic competition with certain of the Company’s products, including potential ANDA filings or patent challenges, and technological changes that may limit demand for the Company’s products. The Company also faces additional risks associated with global and macroeconomic conditions, including health epidemics and pandemics, including risks related to potential disruptions to clinical trials, commercialization activity, supply chain, and manufacturing operations. In addition, such risks and uncertainties may include those described in the Company’s annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC, which are available at the Company’s website (www.travere.com) under “Investors & Media”. You are cautioned not to place undue reliance on any forward-looking statements as there are important factors that could cause actual results to differ materially from those in any forward-looking statements, many of which are beyond the Company’s control. Except to the extent required by law, the Company undertakes no obligation to publicly update any forward-looking statements.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				TRAVERE THERAPEUTICS, INC.
Dated: June 2, 2026				By:		/s/ Eric Dube
				Name:		Eric Dube
				Title:		Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB